Fennec Pharmaceuticals announced the initiation of an investigator-sponsored study by University of Arizona Cancer Center to evaluate PEDMARK in adolescent, young adult, and adult patients with head and neck and testicular cancers receiving cisplatin.
Key takeaways
University of Arizona Cancer Center initiated a Phase I/II study to evaluate PEDMARK as an otoprotectant in adults receiving cisplatin chemotherapy.
The study aims to determine efficacy in reducing hearing impairment and systemic elimination of unbound cisplatin up to 6 hours after infusion.
This is the third institution-led study announced recently, following studies by Tampa General Hospital in March 2026 and City of Hope in December 2025.
Additional investigator-initiated studies supporting PEDMARK use in additional tumor types and patient populations are under review by Fennec.
PEDMARK is currently FDA-approved for pediatric patients one month and older with localized, non-metastatic solid tumors and has NCCN 2A recommendation for AYA patients.